FDA's NDA And BLA Approvals: Nityr, Benlysta
Executive Summary
Original new drugs and biologics recently approved by US FDA.
You may also be interested in...
Finance Watch: $320m In New VC Deals Includes $110m Round For Neogene
Private Company Edition: Neogene, Escient, ESCAPE, Resolution and Attralus raised a combined $320m in venture capital rounds. Also, large Recursion round could double the size of its pipeline, Korro Bio raised $91.5m and Flagship launched Generate Biomedicines.
Samsung Bioepis Quiet On Launch Date After EU Soliris Biosimilar Approval
Samsung Bioepis responded to Generics Bulletin enquiries following its EU-wide approval for a biosimilar to AstraZeneca’s Soliris.
From Inflection To Insight: Vertex And Merck’s Dueling HCV Drugs
Welcome to Inflection to Insight, a new series taking a closer look at notable chapters in biopharma history, gleaning learnings to inform current business strategy. This inaugural instalment looks at the rapid rise and fall of two competing drugs for hepatitis C virus, Vertex’s Incivek and Merck & Co’s Victrelis.